**The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells**
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After the publication of the article, the authors noted that in [Fig. 5c](#f1-ijo-48-02-0854){ref-type="fig"}, the image of β-actin is incorrect. The corrected version of [Fig. 5c](#f1-ijo-48-02-0854){ref-type="fig"} is shown below. In [Fig. 6a](#f2-ijo-48-02-0854){ref-type="fig"}, the histogarms are incorrect, and the corrected [Fig. 6a](#f2-ijo-48-02-0854){ref-type="fig"} is shown below. In [Fig. 7](#f3-ijo-48-02-0854){ref-type="fig"}, the figure of PrEC is incorrect, and the corrected [Fig. 7](#f3-ijo-48-02-0854){ref-type="fig"} (PrEC) is shown below. The corrected figures demonstrate the same findings as the original figures. These corrections do not alter the interpretation of the results and conclusions.
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